Drug–drug interaction related to the use of pipamperon and ondansetron in a child treated for leukemia

Abstract

Pipamperon is a potent neuroleptic drug with many side effects, including prolongation of the QT interval. We report a case of a child treated for leukemia in which prolongation of the QT interval was observed. Physicians and pharmacists should be cautious for drug–drug interactions when pipamperon is prescribed, especially in combination with other QT-prolongating agents. Alternative strategies should be used whenever possible.

Keywords

Pipamperon ondansetron drug–drug interaction leukemia

Get full access to this article

View all access options for this article.

References

Jibson M. Second-generation antipsychotic medications: pharmacology, administration, and side effects. In: Hermann R (ed.) UpToDate. Waltham, MA (accessed 12 January 2017).

Berul C, Seslar P, Zimetbaum P, et al. Acquired long QT syndrome. In: Downey B (ed.) UpToDate. Waltham, MA (accessed 12 January 2017).

Dipiperon. Summary of product characteristics, www.bcfi.be (accessed 21 June 2017).

De Ponti

Poluzzi

Cavalli

et al.

Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002; 25: 263–263.

Drew

Ackerman

Funk

et al.

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047–1047.

Glassman

Bigger

. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158: 1774–1782.

Diagnostic and statistical manual of mental disorders, www.psychiatry.org/psychiatrists/practice/dsm (accessed 21 June 2017).

Horn

Hansten

Chan

. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674–680.

Alizapride. Summary of product characteristics, www.bcfi.be (accessed 21 June 2017).

10.

Drugbank. Pipamperon, www.drugbank.ca/drugs/DB09286 (accessed 21 June 2017).

11.

VigiAccess. Uppsala Monitoring Centre, www.vigiaccess.org (accessed 21 June 2017).

12.

Daviss

Patel

Robb

et al.

Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47: 189–198.

13.

Karz

McGonigle

Goldberg

et al.

Effects of aripiprazole on the QTc: a case report. J Clin Psychiatry 2015; 76: 1648–1649.

14.

Basch

Hesketh

Kris

et al.

Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2011; 7: 395–398.

15.

Tricco

Soobiah

Antony

et al.

Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis. Syst Rev 2013; 2: 46–46.